PBC patients have higher serum levels of IFN-γ and TGF-β than healthy controls [13,14], but therapeutic targeting of IFN-γ in PBC has not demonstrated significant benefit, hinting at the need for novel approaches [8,15]. Here, TGFB1 is linked to primary biliary cholangitis.